Magle Group enters collaboration with Sirtex Medical to support the international commercialization of EmboCept® S DSM 50 µm

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-09-08 16:05, announces the establishment of a collaboration and exclusive worldwide distribution agreement with the global medical device company Sirtex Medial pertaining to its chemoembolization product EmboCept® S DSM 50 µm. The main purpose is to accelerate internationalization, drive growth in new geographic areas, and support the expansion of Magle Group’s product portfolio in this important medical field. Sirtex Medical is a global medical device company focused on improving the quality and longevity of patients’ lives by providing innovative treatment solutions.

The company has over 300 employees and maintains offices and manufacturing facilities in the U.S., Australia, Germany, and Singapore and offers its SIR-Spheres® Y-90 resin microspheres in multiple jurisdictions. EmboCept® S DSM 50 µm has an excellent commercial fit with Sirtex’s current product offering. Magle Group is experiencing a growing international demand for EmboCept® S DSM 50 µm, and the collaboration with Sirtex will facilitate a more powerful and expedited expansion of its commercial footprint. The broader geographical reach will make EmboCept S DSM 50 µm a treatment option for patients in several countries.

Further, the parties will establish a joint development plan to increase the product range in the field of embolization by utilizing Magle Group’s DSM platform. “We are delighted to team up with Sirtex to unleash the full commercial potential of EmboCept S DSM 50 µm, our proprietary product for chemoembolization of inoperable liver and lung tumours.